Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, ...

And as of December 20, Eli Lilly’s weight loss drug Zepbound (tirzepetide) has become the first prescription medication FDA-approved to treat obstructive sleep apnea by increasing airflow and ...

The FDA approval for sleep apnea is ... That equates to 45 to 50 pounds of weight loss, on average, over a year, Lilly said. Patients on the drug also saw reductions in blood pressure and ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has ... knee arthritis pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to severe sleep ...

The Food and Drug Administration expanded the ... that GLP-1 drugs improve overall health along with weight loss. In March, the FDA approved Wegovy, from Novo Nordisk, to reduce heart disease ...

CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.

The Food and Drug Administration approved Eli Lilly’s weight ... according to the FDA. The move comes as weight-loss medications have garnered immense national attention and ignited a debate ...